T cell replacement therapy - Kiadis Pharma

Drug Profile

T cell replacement therapy - Kiadis Pharma

Alternative Names: Allodepleted T-cell ImmunotheRapeutics; ATIR; ATIR-101; ATIR-201; ATIR101; Reviroc™; Rhitol™; T cell replacement therapy TH9402; TH-9402

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator University of Montreal
  • Developer Kiadis Pharma
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Bone marrow transplant rejection; Transplant rejection; Follicular lymphoma; Graft-versus-host disease; B cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Graft-versus-host disease
  • Phase II Acute lymphoblastic leukaemia; Bone marrow transplant rejection; Myelodysplastic syndromes
  • Phase I/II Beta-thalassaemia
  • Discontinued Chronic myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Apr 2017 Kiadis receives regulatory approval for phase I/II trial of ATIR 201 in Germany
  • 03 Apr 2017 Kiadis receives regulatory approval for phase III trial of ATIR 101 in Belgium
  • 28 Mar 2017 Pediatric Committee (PDCO) of the European Medicines Agency (EMA) approves Paediatric Investigation Plan for Haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top